Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
BD makes medical devices and supplies that hospitals, clinics, and labs use every day.
Becton, Dickinson and Company, usually just called BD, sells the unglamorous stuff that keeps medicine running: needles, syringes, IV tubes, blood collection vials, surgical tools, and machines that check whether a patient has an infection or cancer. Its customers are hospitals, clinics, labs, and drug companies, and it makes money in two main ways. One is the Medical segment, which is most of its revenue (roughly 60%), selling disposables like syringes and catheters that hospitals buy in bulk and constantly reorder. The other is the Life Sciences segment, about 40% of revenue, selling lab instruments, diagnostic tests, and prefilled drug-delivery devices to pharmaceutical makers and research labs. Think of it as the plumbing and wiring of healthcare: not the famous part, but almost every hospital and drug trial touches it.
BD dates back to 1897, when two men started making thermometers and syringes in New Jersey, and it grew into a giant by buying its way into new corners of care, most notably its 2017 purchase of C.R. Bard, which made it a major player in catheters and vascular devices. Today it is headquartered in Franklin Lakes, New Jersey, a suburb of New York City, which keeps it close to big hospital systems and Wall Street. The business is steady rather than flashy—people get sick regardless of the economy—so BD generates lots of free cash. It uses that cash to pay dividends, buy back its own stock (recently a few percent of shares a year), pay down debt from big acquisitions, and invest in new products like faster infection tests and smarter drug-delivery systems.
More recently, BD has been shifting its focus. In 2024 it announced it would separate its biosciences and diagnostic solutions business, the lab-testing side, from its medical and drug-delivery business, a move meant to let each half grow faster and be valued on its own merits. It has also been pushing into higher-growth areas like medication management software and advanced drug-delivery devices that pair with the injectable medicines big pharma is launching. The main risks are plain: hospitals squeezing their budgets, pressure on prices from insurers, and the slow, regulated grind of getting new medical devices approved. But as long as people need needles, IV lines, and tests, BD keeps collecting its toll—one small plastic part at a time.
Saved answer · last researched 12 Oct 2026